by Richard Daverman, PhD
July 2, 2012 -- ScinoPharm, the Taiwan-based CMO/CRO, will spend $37.6 million to expand its China operation. The company is building a plant in Tainan Science Park to manufacture high potency cytotoxic compounds that will be used in injectable treatments for cancer. Previously, ScinoPharm specialized in intermediates, APIs and small-batch production of drugs for clinical trials. More details....
Stock Symbol: (TWSE: 1789)
